tiprankstipranks
Trending News
More News >
Clever Leaves Holdings (CLVR)
OTHER OTC:CLVR
US Market

Clever Leaves Holdings (CLVR) AI Stock Analysis

Compare
239 Followers

Top Page

CL

Clever Leaves Holdings

(OTC:CLVR)

Rating:46Neutral
Price Target:
Clever Leaves Holdings faces substantial financial performance challenges, primarily due to ongoing net losses and cash flow issues despite some improvements in gross margins. The strong balance sheet offers some stability, but technical analysis and valuation scores are limited by lack of data and negative profitability. Earnings call insights are neutral, providing little additional impact.

Clever Leaves Holdings (CLVR) vs. SPDR S&P 500 ETF (SPY)

Clever Leaves Holdings Business Overview & Revenue Model

Company DescriptionClever Leaves Holdings Inc. operates as a cannabis company. The company operates through two segments, Cannabinoid and Non-Cannabinoid. The Cannabinoid segment engages in the cultivation, extraction, manufacturing, commercialization, and distribution of cannabinoid products internationally. The Non-Cannabinoid segment is engaged in formulating, manufacturing, marketing, selling, distributing, and commercializing nutraceutical and other natural remedies, wellness products, detoxification products, and nutritional and dietary supplements for mass retailers, specialty and health retailers, and distributors in the United States. The company was founded in 2017 and is based in Boca Raton, Florida.
How the Company Makes MoneyClever Leaves Holdings generates revenue through its diversified business model, which includes the sale of cannabis extracts, such as CBD and THC oils, as well as dried flower and finished goods to pharmaceutical companies, consumer brands, and other enterprises in the cannabis sector. The company capitalizes on its cost-effective production capabilities in Colombia and Portugal to offer competitive prices. Additionally, Clever Leaves engages in strategic partnerships and supply agreements with global entities to expand its market reach and enhance its product distribution. Revenue is further bolstered through its contract manufacturing services, where it offers expertise in formulating and producing cannabis-based products for third-party brands.

Clever Leaves Holdings Financial Statement Overview

Summary
Clever Leaves Holdings shows improved gross profit margins and reduced negative cash flow, but struggles with persistent net losses and negative cash flow. The balance sheet is strong with low leverage, but operational efficiencies need improvement to reach profitability.
Income Statement
40
Negative
The company has shown a declining revenue trend from $17.8M in 2022 to $17.4M in 2023. The gross profit margin improved from 24.3% in 2022 to 37.6% in 2023, indicating better cost management. However, the company faces significant challenges with negative net profit and EBIT margins, reflecting ongoing profitability struggles.
Balance Sheet
55
Neutral
Clever Leaves Holdings has a low debt-to-equity ratio of 0.09, suggesting low financial leverage. However, the return on equity is negative due to net losses, implying a need for improved operational efficiency. The equity ratio of 77.5% in 2023 indicates a strong capital structure with substantial equity backing.
Cash Flow
35
Negative
The company experienced a significant reduction in negative free cash flow from -$30.37M in 2022 to -$11.54M in 2023. Despite this improvement, the negative operating cash flow to net income ratio highlights ongoing cash generation issues.
Breakdown
Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
17.42M17.80M15.37M12.12M7.83M
Gross Profit
6.56M4.33M6.81M7.41M3.10M
EBIT
-15.59M-29.16M-38.70M-26.85M-36.54M
EBITDA
-16.84M-35.80M-35.19M-23.26M-41.72M
Net Income Common Stockholders
-17.90M-66.10M-45.63M-41.41M-48.13M
Balance SheetCash, Cash Equivalents and Short-Term Investments
6.83M12.45M37.23M79.46M12.04M
Total Assets
31.24M52.10M116.16M165.88M95.72M
Total Debt
2.09M3.86M25.09M33.84M33.73M
Net Debt
-4.74M-8.59M-12.13M-45.62M21.68M
Total Liabilities
7.03M11.69M43.39M51.57M45.52M
Stockholders Equity
24.22M40.41M72.77M114.31M45.50M
Cash FlowFree Cash Flow
-11.54M-30.37M-43.51M-25.63M-55.73M
Operating Cash Flow
-11.51M-29.07M-36.23M-21.96M-37.05M
Investing Cash Flow
4.69M1.19M-7.28M-3.67M-33.90M
Financing Cash Flow
656.00K3.29M1.83M91.84M62.83M

Clever Leaves Holdings Risk Analysis

Clever Leaves Holdings disclosed 49 risk factors in its most recent earnings report. Clever Leaves Holdings reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We effected a one-for-thirty reverse share split of our common shares (the "Reverse Share Split"), in August 2023.The Reverse Share Split may adversely impact the liquidity of our common shares and warrants and may not be effective in facilitating our efforts to maintain compliance with the continued listing requirements of Nasdaq. Q4, 2023
2.
We may choose to delist our securities from Nasdaq and deregister under the Exchange Act, which could negatively affect the liquidity and trading prices of our common shares would result in substantially less disclosure about us and severely impair our ability to raise capital. Q4, 2023
3.
We may not be able to obtain import permits in the destination countries or export permits in Colombia in a timely manner or of the required quantities Q4, 2023

Clever Leaves Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
52
Neutral
$339.64M-9.20%-3.02%26.00%
46
Neutral
$702.00-73.91%
44
Neutral
$398.11M-31.06%11.22%-108.58%
40
Neutral
$14.08M-336.65%-28.78%86.97%
39
Underperform
$16.77M-201.88%
30
Underperform
$8.73M-8.46%-9.22%89.90%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CLVR
Clever Leaves Holdings
0.02
-2.99
-99.34%
YCBD
cbdMD
0.96
-4.44
-82.22%
TLRY
Tilray
0.40
-1.38
-77.53%
SNDL
SNDL
1.32
-0.78
-37.14%
FLGC
Flora Growth
0.64
-0.51
-44.35%
IXHL
Incannex Healthcare Limited Sponsored ADR
0.18
-3.18
-94.64%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.